Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study
暂无分享，去创建一个
J. Hampe | J. Maul | R. Atreya | J. Preiß | N. Teich | A. Stallmach | A. Dignass | D. Baumgart | M. Neurath | B. Siegmund | Tony Bruns | F. Hartmann | U. von Arnim | R. Schmelz | H. Schulze | C. Schmidt | K. Ende | C. Langbein